Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.

ABSTRACT:

Background

Neurotoxicity is an established toxicity of CD19 CAR T-cell therapy; however, there is little information on neurotoxicity in children, adolescents, and young adults (CAYA) receiving CD19/CD28ζ CAR T-cells for B-cell malignancies.

Methods

We analyzed neurotoxicity of CD19/CD28ζ CAR T-cells in CAYA treated on a phase I study (NCT01593696). Assessments included daily inpatient monitoring, caregiver-based neuro-symptom checklist (NSC), exploratory neurocognitive assessments, clinically-indicated imaging, CSF analysis, and systematic cytokine profiling, outcomes of which were associated with cytokine release syndrome (CRS) and treatment response postinfusion. Patients with active CNS leukemia were included.

Results

Amongst 52 patients treated, 13 patients had a

SUBMITTER: Shalabi H 

PROVIDER: S-EPMC9435493 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature